A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Launched by UNIVERSITY OF CHICAGO · May 4, 2007
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a group of lung diseases known as Interstitial Lung Diseases (ILD), which includes conditions like Idiopathic Pulmonary Fibrosis, Sarcoidosis, and certain connective tissue disorders. The goal is to gather information and blood samples from patients who are receiving care for these diseases, as well as from a group of healthy individuals for comparison. By doing this, researchers hope to better understand how these diseases develop and affect patients.
To participate in this study, individuals must be diagnosed with an Interstitial Lung Disease. The trial is open to all adults aged 65 to 74. Participants can expect to provide some blood samples and share information about their health, which will help researchers learn more about these conditions. It's important to note that this study is currently recruiting new participants, and being involved can contribute to advancing knowledge about ILD and improving future treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Interstitial lung disease
- Exclusion Criteria:
- • Does not have Interstitial lung disease
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Mary E Strek, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials